These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 17929112)

  • 41. Treatment of acute promyelocytic leukemia for older patients.
    Prebet T; Gore SD
    J Natl Compr Canc Netw; 2011 Mar; 9(3):337-42. PubMed ID: 21393443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
    Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
    Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
    Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
    Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute promyelocytic leukemia in childhood.
    Gregory J; Feusner J
    Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
    Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
    Chen Y; Gu L; Zhou C; Wu X; Gao J; Li Q; Zhu Y; Jia C; Ma Z
    Int J Hematol; 2010 May; 91(4):708-10. PubMed ID: 20405253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)].
    Moreno Tejero ML; Lassaletta Atienza A; García Salido A; Sevilla Navarro J; Madero López L
    An Pediatr (Barc); 2010 Jul; 73(1):39-41. PubMed ID: 20605542
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute promyelocytic leukemia: from highly fatal to highly curable.
    Wang ZY; Chen Z
    Blood; 2008 Mar; 111(5):2505-15. PubMed ID: 18299451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells.
    Côté S; Rosenauer A; Bianchini A; Seiter K; Vandewiele J; Nervi C; Miller WH
    Blood; 2002 Oct; 100(7):2586-96. PubMed ID: 12239173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
    Baba SM; Shah ZA; Pandith AA; Dil-Afroze ; Jan A; Mir KA; Aziz SA; Ahmad Z
    Cancer Genet; 2019 Feb; 231-232():14-21. PubMed ID: 30803552
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study.
    Visani G; Buonamici S; Malagola M; Isidori A; Piccaluga PP; Martinelli G; Ottaviani E; Grafone T; Baccarani M; Tura S
    Leukemia; 2001 Nov; 15(11):1696-700. PubMed ID: 11681409
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autophagic degradation of an oncoprotein.
    Bøe SO; Simonsen A
    Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What is the role of arsenic in newly diagnosed APL?
    Tallman MS
    Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
    Jing Y; Xia L; Waxman S
    Blood; 2002 Aug; 100(3):1008-13. PubMed ID: 12130515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
    Niu C; Yan H; Yu T; Sun HP; Liu JX; Li XS; Wu W; Zhang FQ; Chen Y; Zhou L; Li JM; Zeng XY; Yang RR; Yuan MM; Ren MY; Gu FY; Cao Q; Gu BW; Su XY; Chen GQ; Xiong SM; Zhang TD; Waxman S; Wang ZY; Chen Z; Hu J; Shen ZX; Chen SJ
    Blood; 1999 Nov; 94(10):3315-24. PubMed ID: 10552940
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular Characteristics and Clinical Significance of 12 Fusion Genes in Acute Promyelocytic Leukemia: A Systematic Review.
    Yan W; Zhang G
    Acta Haematol; 2016; 136(1):1-15. PubMed ID: 27089249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
    Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
    Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia.
    Zhu HH; Qin YZ; Lai YY; Shi HX; Liu YR; Jiang B; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):872-8. PubMed ID: 23998577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Curing APL: differentiation or destruction?
    Kogan SC
    Cancer Cell; 2009 Jan; 15(1):7-8. PubMed ID: 19111876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.